Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Summit Therapeutics Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.74B), while Summit Therapeutics Inc trades at $17.32 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 7.9× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is more actively traded (9,289,619 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| NUVB | SMMT | |
|---|---|---|
Market Cap | $1.74B | $13.71B |
Volume | 9,289,619 | 6,173,057 |
Sector | Health | Health |
52-Week High | $9.54 | $26.38 |
52-Week Low | $3.41 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $1.33B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
